Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.32 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302674 | 1.00 | SLC13A5 (0.40) | SLC13A5SMN1; SMN2CYP2C19HIF1AKEAP1 | |
| SCHEMBL6302907 | 0.83 | SMN1; SMN2 (0.33) | SLC13A5SMN1; SMN2P2RX7PDCD1CD274 | |
| SCHEMBL6297903 | 0.81 | NLRP3 (0.39) | SMN1; SMN2POLBRIPK1 | |
| SCHEMBL6297901 | 0.81 | NLRP3 (0.39) | SMN1; SMN2POLBRIPK1 | |
| SCHEMBL6296754 | 0.78 | SLC13A5 (0.43) | SLC13A5CYP2C19HIF1APDCD1CD274 | |
| SCHEMBL6296751 | 0.78 | SLC13A5 (0.43) | SLC13A5CYP2C19HIF1APDCD1CD274 | |
| SCHEMBL6693952 | 0.78 | SLC13A5 (0.43) | SLC13A5CYP2C19HIF1APDCD1CD274 | |
| SCHEMBL6296103 | 0.77 | SLC13A5 (0.45) | SLC13A5 | |
| SCHEMBL6296538 | 0.76 | NR3C2 (0.38) | SLC13A5P2RX7 | |
| SCHEMBL6696484 | 0.76 | NR3C2 (0.38) | SLC13A5P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | SLC13A5 4373/4885SMN1; SMN2 4359/4885CYP2C19 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.